27 April 2009 - Asterand has announced that it has entered into a collaborative agreement with Abcam to characterise antibodies.
Asterand will undertake the validation and characterisation of a selected group of Abcam antibodies for immuno-histochemistry applications using Asterand's Phasezero Human Tissue Services platform.
Asterand will utilise its Target Evaluator database to pinpoint the expression patterns of selected antibody targets across a panel of human tissue types.
